The rising incidence of obesity requires the reevaluation of our current therapeutic strategies to optimize patient outcomes. The objective of this study was to determine whether compositional and functional characteristics of the gut microbiota in adults predict responses to a comprehensive lifestyle intervention program in overweight and obese adults. We recruited 26 participants from the Mayo Clinic Obesity Treatment Research Program between August 6, 2013, and September 12, 2013, to participate in a lifestyle intervention program for weight loss. Adults aged 18 to 65 years with a body mass index of 27 to 39.9 kg/ m 2 and able to provide informed consent were included in the study. Fecal stool samples were obtained at baseline and after 3 months. Loss of at least 5% of baseline weight after 3 months was defined as success. Clinical characteristics and gut microbial composition and function were compared between those who achieved at least 5% and those who achieved less than 5% weight loss. After 3 months, 9 of 26 participants lost at least 5% of their weight. The mean weight loss was 7.89 kg (95% CI, 6.46-9.32 kg) in the success group and 1.51 kg (95% CI, 0.52-2.49 kg) in the less than 5% weight loss group. An increased abundance of Phascolarctobacterium was associated with success. In contrast, an increased abundance of Dialister and of genes encoding gut microbial carbohydrate-active enzymes was associated with failure to lose 5% body weight. A gut microbiota with increased capability for carbohydrate metabolism appears to be associated with decreased weight loss in overweight and obese patients undergoing a lifestyle intervention program.
O besity is a chronic disease that is increasing in prevalence around the world and is now considered a global epidemic. Obesity, as measured by body mass index (BMI, calculated as the weight in kilograms divided by the height in meters squared) of 30 kg/m 2 or greater, has been consistently associated with increased all-cause mortality. 1 A comprehensive lifestyle intervention is usually the first step for achieving weight loss. A weight loss of just 5% through a combination of dietary restrictions, physical exercise, and behavioral therapy is effective in achieving better glycemic control and preventing diabetes. 2, 3 However, there is marked interindividual variability in the success of this approach that has often been attributed to patient adherence. 4 The pathophysiology of obesity is complex, with contributions from host genes as well as environmental factors. 5 Recent evidence suggests that the human gut microbiome has a role in the pathophysiology of obesity by influencing host energy metabolism, adiposity, 6 neuroendocrine signaling, and insulin sensitivity. 7 Hence, the gut microbiome may be responsible in part for the interindividual differences in outcomes of obesity-directed interventions. In this study, we report potential microbial markers that predict responses to a comprehensive lifestyle intervention program for weight loss.
PATIENTS AND METHODS

Patient Selection
Patients were recruited between August 6, 2013 , and September 12, 2013 , from the Mayo Clinic Obesity Treatment Research Program. Adults aged 18 to 65 years with a BMI of 27 to 39.9 kg/m 2 and able to provide informed consent were included in the study. The exclusion criteria included health problems that prevented individuals from engaging in physical activity, previous operations for managing obesity (bariatric procedures and gastric bypass operation), concurrent participation in another weight loss program, and use of weight loss medications within the previous 30 days. Participants with any use of antibiotics within the previous 30 days were also excluded from the analysis. Other medications such as proton pump inhibitors, laxatives, statins, and analgesics were allowed. None of the included participants were taking probiotics.
Study Interventions
The Mayo Clinic Obesity Treatment Research Program is a 12-month comprehensive lifestyle intervention program. During the first 3 months, participants were followed through weekly 1-hour sessions, biweekly in the fourth month, and monthly thereafter until 12 months. To minimize the effect of participant nonadherence on the results, we selected the first 3 months as the time frame of our study. The nutritional intervention involved a volumetric approach 8 that included larger amounts of fruits, vegetables, and low energy density foods with lesser intake of foods with greater nutrient density. The goal was to reduce energy intake while achieving a high food intake volume.
The physical activity intervention involved recommendations to walk at least 10,000 steps per day or its equivalent. Physical activity was monitored using a pedometer with 7-day memory. Patients were instructed to wear the pedometer every day and review their step count data to assess progress toward the goal.
The behavioral intervention was given in weekly group sessions and included elements such as self-monitoring, managing expectations, goal setting, stimulus control, stress reduction, problem solving, social support, cognitive restructuring, and relapse prevention.
The general outline of the sessions was based on the Look AHEAD protocol. 9 Outcome Measures and Data Processing Clinical, biochemical, and demographic information was collected from patients at baseline and after 3 months, including age, sex, race, weight, height, BMI, smoking status, hypertension, prediabetes, type 2 diabetes, fasting blood glucose, high-density lipoprotein levels, low-density lipoprotein levels, and triglyceride levels. The percent weight loss after 3 months was calculated on the basis of the participant's baseline body weight. A 5% or greater weight loss after 3 months was defined as success. Fecal stool samples were collected at baseline and after 3 months.
DNA isolation from stool samples was performed using the PowerSoil DNA Isolation Kit (Mo Bio Laboratories) after bead beating. The V4 variable region of bacterial 16S ribosomal ribonucleic acid (rRNA) was amplified from stool DNA and sequenced with the MiSeq platform (Illumina). Compositional and diversity data analysis was performed using the Quantitative Insights into Microbial Ecology (QIIME, version 1.9.1) pipeline. 10 Predictive functional profiling from 16 rRNA was performed using the Phylogenetic Investigation of Communities by Reconstruction of Unobserved States pipeline. 11 Gene content was predicted against the following databases: the Kyoto Encyclopedia of Genes and Genomes database, 12 the Clusters of Orthologous Groups database, 13 and the Carbohydrate-Active Enzymes database.
14 The linear discriminant analysis (LDA) effect size (LEfSe) method 15 was developed to identify predictive compositional and functional biomarkers for weight loss. An a value of .05 and an LDA threshold of greater than 2.0 were used.
Statistical Analyses
Statistical analyses were performed using JMP Pro 12 software (SAS Institute) and the Quantitative Insights into Microbial Ecology pipeline. Twosided Wilcoxon rank-sum tests were used to compare baseline differences in bacterial composition and a diversity, whereas permutational multivariate analysis of variance was used for b diversity. For interval changes in bacterial composition and diversity between baseline and after 3 months, 2-sided Wilcoxon signed-rank tests were used. A P value of .05 or less was considered statistically significant for all tests.
RESULTS
Clinical Characteristics Do Not Predict
Response to Lifestyle Intervention Forty-seven participants volunteered for the study. Twenty-six of 47 participants (55%) were included in the analysis, and 21 participants (45%) were excluded for the following reasons: did not return at least 1 of their stool samples (n¼16; 76%), did not return their stool samples on time and hence are not representative of their baseline gut microbiota (n¼3; 14%), provided insufficient stool sample for the analysis (n¼1; 5%), or dropped from the study (n¼1; 5%). Excluded patients were not significantly different from included patients in terms of age (P¼.30), sex (P¼.73), and race (P>.99).
Of the 26 participants included in the analysis, 4 were overweight and 22 were obese. The mean age of all participants was 53.5 years (95% CI, 50.3-56.8 years), with 81% of participants being female. The mean weight at baseline was 95.7 kg (95% CI, 90.0-101.4 kg), and the mean BMI at baseline was 34.1 kg/m 2 (95% CI, 32.6-35.8 kg/m 2 ). At 3 months, the mean weight loss was 3.71 kg (95% CI, 2.31-5.11 kg) and the mean reduction in BMI was 1.27 kg/m 2 (95% CI, 0.69-1.87 kg/m 2 ), with 9 participants (35%; 95% CI, 19%-54%) achieving at least 5% weight loss in 3 months. There was no considerable difference in the proportion of participants who achieved at least 5% weight loss compared with those who did not. Participants who lost at least 5% of their weight lost an average of 7.89 kg (95% CI, 6.46-9.32 kg), and those who lost less than 5% of their baseline weight lost an average of 1.51 kg (95% CI, 0.52-2.49 kg). After 6 months, a total of 8 of 9 participants who lost at least 5% of their baseline weight at 3 months maintained the weight loss. Two of these 8 participants were able to achieve 10% weight loss after 6 months. A comparison of baseline clinical, biochemical, and demographic characteristics between participants at 3 months is shown in Table 1 . There were no significant differences in these variables at baseline or at 3 months between those who achieved at least 5% weight loss and those who did not. There were also no associations between baseline clinical, biochemical, and demographic characteristics with losing at least 5% of baseline weight after 3 months.
Compositional Differences Within the Veillonellaceae Family at Baseline Were Associated With At Least 5% Weight Loss Microbial compositional analysis using LEfSe identified 2 members of the gut microbiota that were significantly different between the groups. Phascolarctobacterium was significantly increased at baseline in participants who lost at least 5% weight loss after 3 months (LDA score, 2.09; P¼.008) and Dialister was significantly increased in those who achieved less than 5% weight loss (LDA score, À2.07; P¼.03) (Figure) .
A Gut Microbiota With Increased Capacity for Carbohydrate Metabolism at Baseline Was Associated With Failure to Lose At Least 5% of Baseline Weight
We imputed gut microbiota functionality from compositional data using the Phylogenetic Investigation of Communities by Reconstruction of Unobserved States pipeline ( Table 2 ). The abundance of predicted genes was then analyzed through LEfSe to identify biomarkers of weight loss. We identified a gene encoding a transposase (COG3328) that was predictive of success ( Figure C) . We also identified 6 bacterial genes encoding carbohydrate-active enzymes and binding proteins that were predictive of less than 5% weight loss after 3 months. These included 2 glycoside hydrolase families (GH67 and GH93), 2 carbohydrate-binding module families (CBM51 and CBM58), a carbohydrate esterase family (CE6), and a glycosyltransferase family (GT25) ( Figure D) .
Baseline Gut Microbial Diversity Is Similar Regardless of Achieved Weight Loss After 3 Months
An analysis of baseline gut microbial diversity between the 2 groups revealed no significant differences in a diversity (observed operational taxonomic units, Shannon index, and Chao1 metrics) or b diversity (Bray-Curtis dissimilarity and unweighted and weighted UniFrac). 
No Observed Change in Gut Microbial
Composition and Diversity After 3-Month Intervention To determine whether weight loss during a lifestyle intervention program led to changes in gut microbiota composition, we analyzed interval changes in gut microbial composition and diversity after 3 months. There were no significant changes in a diversity (observed operational taxonomic units, Shannon index, and Chao1 metrics) or b diversity (Bray-Curtis dissimilarity and unweighted and weighted UniFrac) or bacterial composition in either group of patients.
DISCUSSION
In this study, we identified compositional and predicted functional bacterial profiles that were associated with more than 5% weight loss responses in overweight and obese adults undergoing a lifestyle intervention program. An increased baseline abundance of Phascolarctobacterium was associated with a weight loss of at least 5%, whereas an increased abundance of Dialister was associated with a weight loss of less than 5%. Interestingly, both genera belong to the Veillonellaceae family, which suggests that compositional shifts within this family may have a role in host energy metabolism. We also found that an increased abundance of several carbohydrate-metabolizing enzymes was associated with outcomes. Phascolarctobacterium is a relatively abundant genus of bacteria in the human gastrointestinal tract. 16 In terms of its role in energy metabolism and obesity, a previous study with obese rats found that an increased abundance of Phascolarctobacterium correlated positively with body weight gain, fat mass, plasma leptin levels, increased triglyceride concentrations, and increased glucose tolerance 17 after receiving a high-fat diet. Interestingly, although Phascolarctobacterium is associated with obesity in previous reports, our study suggests that it may potentiate the effect of lifestyle and dietary interventions on weight loss.
In contrast, Dialister is a pathogenic genus of bacteria associated with oral infections, such as periodontitis, gingivitis, and dentoalveolar abscesses. [18] [19] [20] However, the role that Dialister may have in energy expenditure and metabolism is unknown. The fact that both belong to the same family suggests that there might be a nutritional niche competition by which Dialister excludes Phascolarctobacterium. Despite these compositional findings, we were unable to detect significant differences in a or b diversity between both groups of participants. However, the functional differences associated with carbohydrate metabolism may have a greater role in influencing weight loss than shifts in microbial diversity. However, future studies are needed to validate these findings and better understand a role of these genera in energy metabolism.
Functional analyses using the CarbohydrateActive Enzymes database revealed that participants who achieved less than 5% weight loss had significantly increased abundances of enzymes involved in carbohydrate metabolism. Carbohydrate-binding modules are polypeptides that bind carbohydrate substrates and facilitate enzymatic reactions, such as those of glycoside hydrolases, by holding the enzyme close to the substrate. CBM51 is a family of diverse carbohydrate-binding molecules known to bind blood group A and B antigens, 21 and CBM58 is characterized by starch utilization system G, an a-amylase essential for starch degradation. Starch utilization system G is part of the Sus protein group that work together in polysaccharide recognition and import into bacterial cells. 22 Glycoside hydrolases present in human gut microbiota are essential for digesting carbohydrates that humans cannot process. GH67 and GH93 catalyze the hydrolysis of xylooligosaccharides 23 and linear a-1,5-L-arabinan, 24 respectively. This is a pilot study, and hence it is limited by a small sample size. In addition, we limited our analysis to the first 3 months. Although Carbohydrate-active enzymes associated with failure to lose 5% of weight in 3 mo.
these findings highlight a potential approach to individualizing management for obesity using the gut microbiome, they need to be confirmed in a larger cohort with longitudinal follow-up. The volumetric approach used in this study as part of the nutritional intervention allows for more dietary variability between participants, which may confound the results, given the known effect of diet on the gut microbiome. However, gut microbial differences related to diet have been found to be significant across different continents but not between adults from different regions in the United States. 25 Participants were largely from the same region; thus, we expect the effect of dietary variability on the gut microbiota between participants to be minimal. Finally, in this preliminary report we present data using the 16S rRNA markerbased approach, but a future study would require metagenomics and metabolomics to confirm functional consequences of the potential differences in carbohydrate metabolism.
CONCLUSION
An increased abundance of microbial genes encoding carbohydrate-active enzyme pathways and a decreased abundance of Phascolarctobacterium in the gut microbiota of obese and overweight individuals are associated with failure to lose at least 5% weight following a 3-month comprehensive lifestyle intervention program.
